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ABSTRACT OF DISSERTATION 
 
 
 
SURVIVAL AND INFLAMMATION IN PATIENTS WITH HEART FAILURE: THE IMPACT 
OF OVERWEIGHT, OBESITY, DIABETES AND FRUIT AND VEGETABLE 
CONSUMPTION  
 
 Overweight and obesity are paradoxically associated with better survival in 
patients with heart failure (HF). This association is poorly understood, in part because 
the impact of diabetes (DM) on survival of overweight and obese HF patients has not 
been considered. Inflammation may contribute to worse survival in overweight and 
obese HF patients with DM, and levels of inflammation may be associated with fruit and 
vegetable consumption. However, neither of these relationships has been investigated in 
patients with HF.  
 
 The purposes of this dissertation were to a) examine the effect of DM on survival 
of overweight and obese patients with HF, b) explore potential inflammatory-related 
factors that underlie differences in survival of overweight and obese HF patients with and 
without DM and c) examine the association between nutrition and inflammation in 
patients with HF. To address these purposes three investigations were conducted: 1) 
comparison of event-survival (the combined endpoint of all cause hospitalization and 
death) of normal weight HF patients without DM to overweight and obese HF patients 
with and without DM 2) comparison of levels of inflammatory markers in overweight and 
obese patients with DM to normal weight, overweight and obese patients without DM 3) 
determination of the association of fruit and vegetable consumption with levels of 
inflammatory markers in patients with HF.  
 
 In the presence of DM, patients who were overweight and obese had increased 
risk of all cause hospitalization and death. Obese patients without DM had similar risk as 
normal weight patients without DM. Overweight and obese patients with DM had higher 
levels of some, but not all, inflammatory markers compared with normal weight, 
overweight and obese patients without DM. Higher vegetable, but not fruit consumption 
was associated with lower levels of some inflammatory markers.  
 
 This dissertation has addressed an important gap in the current evidence by 
demonstrating the contribution of DM to all cause hospitalization and death in overweight 
and obese patients with HF. This investigation has also demonstrated that higher levels 
of inflammation may contribute to differences in survival between these groups. 
 
 
 
Increasing vegetable consumption may be one avenue to lowering inflammation in 
patients with HF.  
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CHAPTER ONE: 
Introduction 
1. The impact of overweight, obesity and diabetes on survival of patients with 
heart failure  
Heart failure (HF) affects 5.8 million people in the United States (U.S.), and 
670,000 new cases are diagnosed each year.1 The estimated direct and indirect cost of 
HF for 2010 is $39.2 billion,1 but more importantly HF is also costly in terms of morbidity 
and mortality. It is the fourth most common cause of hospitalization in the U.S.,2 and 
approximately 59% of men and 45% of women die within five years of HF diagnosis.1  
Investigators in the Framingham Heart Study identified overweight and obesity as 
risk factors for the development of HF. After adjusting for known risk factors, 
investigators found that obesity doubled the risk for the development of HF among the 
5581 participants. In women, overweight increased risk by 50%.3 In contrast with our 
current understanding of the effects of overweight and obesity on morbidity and 
mortality,4 the results of nine studies involving over 130,000 patients with HF 
demonstrated that overweight and obese patients have better survival compared with 
normal weight patients.5-13  
Several putative explanations exist for this paradoxical relationship. Obesity may 
provide an increased metabolic reserve that helps patients withstand the catabolic 
stresses of HF. Obese patients may have lesser increases in neurohormonal activation, 
increased tolerance to angiotensin converting enzyme inhibitors, altered inflammatory 
cytokine profiles or higher cholesterol levels that may decrease inflammation. All of 
these may confer a better prognosis to overweight or obese patients with HF,11, 14 but 
none have been tested which limits our understanding of the mechanisms underlying the 
obesity paradox.  
Another factor limiting understanding of the obesity paradox is that the impact of 
obesity associated comorbidities, such as diabetes (DM) on survival of overweight and 
obese patients has not been considered. DM is a common comorbidity in patients with 
HF, with prevalence rates as high as 30%,15 and it is associated with increased risk of 
death16-23 and HF hospitalization16, 17, 19 in patients with HF. The majority of the previous 
investigators of the obesity paradox have controlled for DM in survival analysis.5, 7, 10-12 
Consequently, the results of these studies reflect survival of overweight and obese 
patients independently of DM. No investigation has yet examined outcomes in 
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overweight and obese patients with DM compared to normal weight patients without DM, 
and as such the impact of DM among these groups is unknown.  
The current evidence on the obesity paradox is further limited because most 
investigators have examined only all cause or cardiac related death.5-9 Two groups have 
investigated all cause hospitalization10, 12 and only one has examined the combined 
endpoint of all cause hospitalization and death.11 All three controlled for the presence of 
DM; as a result the impact of DM on this outcome has been obscured. Because 
overweight, obesity24-26 and DM27, 28 can contribute to cardiac and non-cardiac 
morbidity24, 27 and mortality,25-28 it is important to look at both hospitalization and death 
from cardiac and non-cardiac causes in overweight and obese patients with and without 
DM. Studies of this type would provide a more complete picture of survival.  
These gaps in the available evidence have contributed to a lack of consensus 
regarding body weight recommendations among the HF management guidelines. The 
American Heart Association/American College of Cardiology guidelines are silent 
regarding body weight recommendations for overweight and obese patients.29 The 
European Society of Cardiology guidelines suggest weight loss for obese patients only,30 
while the Heart Failure Society of America recommends weight loss only for those with 
obesity associated syndromes such as obesity cardiomyopathy or obesity 
hypoventilation syndromes.31 Studies examining the impact of DM on all cause 
hospitalization and death of overweight and obese patients with HF are needed to 
address current knowledge gaps and inform sound body weight recommendations in 
patients with HF.  
2. Inflammation in heart failure and diabetes  
Higher levels of inflammation in overweight and obese HF patients with DM may 
contribute to poorer survival, either through effects on the myocardium or through 
contribution to DM related microvascular complications. Levine et al32 published one of 
the first studies demonstrating elevated levels of tumor necrosis factor alpha (TNFα) in 
patients with HF. In 33 patients with chronic HF, mean TNFα levels were 13 times higher 
than levels in age-matched healthy controls. Subsequently, several other investigators 
have found higher levels of TNFα33-36 and its two soluble receptors, sTNF-R137-40 and 
sTNF-R2,33, 35, 38, 39 in patients with HF. TNFα may contribute to the progression of HF 
through its negative inotropic effects and by contributing to cardiac remodeling.41 Higher 
levels of TNFα42 and its soluble receptors40, 43 are predictive of worse survival in patients 
with HF.  
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Higher levels of TNFα have also been reported in patients with DM compared 
with non-DM controls.44-47 Although its role is still being clarified, TNFα may contribute to 
the complications associated with DM including retinopathy,48 neuropathy49 and 
nephropathy.50 Higher levels of TNFα,51-53 sTNF-R1 and sTNF-R254 have been 
demonstrated in DM patients with these complications compared with DM patients 
without these complications. Further, mouse models suggest that increased levels of 
reactive oxygen species (ROS) may be present in the DM heart.55 Oxidative stress not 
only promotes myocardial injury directly, but can also induce increases in inflammation.56 
Higher levels of inflammation in overweight and obese HF patients with DM may 
be an underlying reason for differences in survival among these groups. However, 
investigators exploring inflammatory markers in patients with HF have not investigated 
the impact of DM on levels of inflammation. Similarly, none of the investigations 
exploring inflammatory markers in DM patients have been conducted in patients with HF 
as a comorbidity. Research is needed to determine if overweight and obese HF patients 
with DM have higher levels of inflammation compared with HF patients without DM. 
Exploring this question will help to identify potential avenues for improving outcomes in 
HF patients with DM.  
 3. Fruit and vegetable consumption and inflammation  
Fruits and vegetables may provide an avenue for altering the inflammatory status 
of HF patients with and without DM, potentially through their antioxidant compounds. 
Oxidative stress promotes the binding of the transcription factor nuclear factor-kappa B 
(NF-κB) to DNA and the subsequent production of proinflammatory cytokines.57  
Antioxidants inhibit oxidative stress by neutralizing free radicals and reactive oxygen 
species58 and may thereby block the synthesis of inflammatory cytokines and 
subsequent inflammation. Several nutrients found in fruits and vegetables  have 
antioxidant capabilities such as vitamin C, vitamin E and the carotenoids (i. e. beta-
carotene, lycopene, zeaxanthin, lutein).58 However, fruits and vegetables are also 
sources of other phytochemicals including polyphenols,59 which demonstrate antioxidant 
and anti-inflammatory properties such as inhibiting NF-κB.60 Thus fruits and vegetables 
contain a variety of compounds that may alter inflammatory status.  
Several studies have demonstrated that higher fruit and vegetable consumption 
is associated with lower levels of inflammatory markers in non-HF populations. Gao and 
collegues61 investigated this relationship in 599 elders. A significant dose-response 
between increasing fruit and vegetable intake and decreasing plasma C-reactive protein 
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levels was demonstrated after controlling for the presence of DM and cardiovascular 
disease. Subsequent studies have also demonstrated this relationship for fruits62, 63 and 
vegetables.63 More recently the association between fruits and vegetables and TNFα 
has been investigated. Holt et al64 demonstrated that TNFα levels were inversely 
associated with vegetable consumption in 285 adolescents after controlling for age, 
gender, race, energy intake and body mass index. This relationship has not been 
investigated in patients with HF, but has important implications for this patient 
population. TNFα is a primary contributor to the pathogenesis of HF65 and higher levels 
of TNFα have been associated with poorer survival of patients with HF.40, 42, 43  
Investigating the association between fruit and vegetable consumption and levels of 
TNFα could identify a means of lowering inflammation and improving survival in patients 
with HF.  
In sum, overweight and obesity are associated with better survival in patients 
with HF, but our understanding of this relationship is limited, in part because the impact 
of DM on all cause hospitalization and death of overweight and obese patients has not 
been investigated. Higher levels of inflammatory cytokines may contribute to worse 
survival in overweight and obese HF patients with DM either through effects on the 
myocardium or by contributing to microvascular damage. Although higher levels of 
inflammatory markers have been documented both in patients with HF and in patients 
with DM compared to normal controls, no study has yet investigated whether HF patients 
with DM have higher levels of inflammatory markers compared to HF patients without 
DM. In addition, levels of inflammatory markers have been associated with fruit and 
vegetable consumption, however it is unknown if this association exists in patients with 
HF. Identifying this relationship could provide a potential route to lowering inflammation 
and improving survival in HF patients with and without DM.  
Therefore the purposes of this dissertation were to 1) examine the effect of DM 
on survival of overweight and obese patients with HF 2) determine differences in 
inflammation of overweight and obese HF patients with and without DM and 3) 
determine if fruit and vegetable consumption was associated with levels of inflammation 
in patients with HF. Three studies were conducted to address these purposes. First, the 
impact of DM on all cause hospitalization and death of overweight and obese patients 
was determined by comparing survival of normal weight HF patients without DM to 
overweight and obese HF patients with and without DM. Second, levels of inflammatory 
markers in overweight and obese patients with DM were compared to levels in normal 
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weight, overweight and obese patients without DM. Third, the association of fruit and 
vegetable consumption with levels of inflammatory markers in all patients with HF was 
determined.  
4. Summary of chapters  
Chapter Two is an investigation of the impact of DM on survival of overweight 
and obese HF patients. Three hundred thirty-eight patients recruited from HF clinics 
were stratified into five groups (normal weight without DM, overweight without DM, 
overweight with DM, obese without DM and obese with DM) and followed for a maximum 
of four years (mean follow-up time of 389 days). Hospitalization and death were 
determined by patient/family interview and medical record review. Cox regression 
analysis was used to determine differences in the combined endpoint of all cause 
hospitalization and death. Survival of overweight and obese patients with and without 
DM was compared to normal weight patients without DM. The results demonstrated that 
overweight and obese HF patients with DM and overweight patients without DM had 
double the risk of having an event compared with normal weight patients. However, 
obese patients without DM had similar survival compared with normal weight patients.  
Chapter Three is a comparison of levels of inflammatory markers in overweight 
and obese patients with and without DM to normal weight patients without DM. A total of 
343 patients were recruited from HF clinics and were again stratified into five groups 
(normal weight without DM, overweight without DM, overweight with DM, obese without 
DM and obese with DM). Plasma levels of sTNF-R1 and sTNF-R2 were determined in all 
patients. Obese patients with DM had significantly higher levels of sTNF-R1 compared 
with all three non-DM groups. Similarly, overweight patients with DM had significantly 
higher levels of sTNF-R1 compared with overweight and obese patients without DM. 
Obese patients with DM had significantly higher levels of sTNF-R2 compared with 
overweight and obese patients without DM, but there were no differences in sTNF-R2 
levels between overweight DM patients and any group.  
Chapter Four is an investigation of the association between fruit and vegetable 
consumption and levels of sTNF-R1 and sTNF-R2 in patients with HF. A total of 221 
patients with HF were recruited from HF clinics. Fruit and vegetable consumption was 
determined using weighed four day food diaries, and plasma levels of sTNF-R1 and 
sTNF-R2 were measured in all patients. Logistic regression controlling for age, gender, 
NYHA class, DM, body mass index, waist circumference and energy intake revealed that 
higher vegetable, but not fruit consumption was associated with a lower risk of having 
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elevated sTNF-R1 levels. Fruit and vegetable consumption was not associated with 
higher levels of sTNF-R2.  
 Chapter Five is a synthesis of the results of the preceding chapters and a 
discussion of how this body of work advances the state of the science regarding obesity, 
DM, inflammation and nutrition in patients with HF. Clinical and research implications are 
also discussed.  
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CHAPTER TWO: 
Increased Risk of All Cause Hospitalization and Death in Overweight and Obese 
Patients with Heart Failure: The Impact of Diabetes as a Comorbidity  
1. Synopsis 
 Overweight and obesity are paradoxically associated with better survival in 
patients with heart failure (HF). However, overweight and obesity are also associated 
with diabetes mellitus (DM), a comorbidity that increases risk of hospitalization and 
death in patients with HF. The impact of DM on survival of overweight and obese HF 
patients with DM has not been described.  
 The purpose of this investigation was to compare event-free survival (all cause 
hospitalization and death) of overweight and obese HF patients with and without DM to 
normal weight patients without DM.  
 A total of 338 patients recruited from HF clinics were followed for hospitalization 
and death. Weight and height were measured using professional grade scales and 
stadiometers. Body mass index (BMI) was calculated as weight in kilograms/height in 
meters2. The diagnosis of DM was determined by patient report and confirmed by 
medical record review. Patients were stratified into 5 groups: normal weight (18.5-24.9 
kg/m2) without DM (n=54), overweight (25-29.9 kg/m2) without DM (n=60), overweight 
with DM (n=36), obese (≥ 30 kg/m2) without DM (n=92) and obese with DM (n=96). Cox 
regression was used to compare differences in event-free survival among groups.  
 Forty-one percent of patients experienced an event. There was no significant 
difference in all cause hospitalization and death between obese patients without DM and 
normal weight patients without DM controlling for age, gender, NYHA class, LVEF, ACE 
inhibitor use, and depressive symptoms (p=.2). In contrast, obese patients with DM, 
overweight patients with DM and overweight patients without DM had double the risk for 
all cause hospitalization and death compared to the normal weight group (HR=2.09 95% 
CI=1.14-3.83; HR= 2.05 95% CI =1.02-4.12; HR=2.13, 95% CI=1.12-4.05).  
 The results of this investigation suggest that obesity does not increase risk of all 
cause hospitalization and death in patients with HF. However, obese patients with DM 
and overweight patients with and without DM are at increased risk for all cause 
hospitalization and death.  
2. Introduction   
 Results of the Framingham Heart Study demonstrated that greater body mass 
index is independently associated with increased risk of heart failure (HF).1 These 
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results are in line with our current understanding of the contribution of overweight and 
obesity to mortality and morbidity.2, 3 In contrast, recent evidence indicates that 
overweight and obese patients with established HF have decreased mortality risk when 
compared with normal weight patients with HF.4-12 This counterintuitive relationship has 
been described as the obesity paradox.  
Overweight and obesity are also associated with increased risk for diabetes 
mellitus (DM).2 DM is a common comorbidity in patients with HF with prevalence rates 
estimated as high as 30%.13-16 DM increases the risk for hospitalization17-19 and all cause 
mortality14, 17-24 in patients with HF. The majority of investigators demonstrating the 
obesity paradox controlled for the presence of DM in their analyses.4, 5, 8, 10, 11 
Subsequently the contribution of DM to outcomes has not been examined. Similarly, the 
majority of investigators examining the impact of DM on outcomes in patients with HF 
have controlled for body mass index (BMI),17, 19-21, 23, 24 but none considered the 
contribution of overweight and obesity to outcomes among patients with and without DM. 
To increase our understanding of the relationship between obesity and outcomes in HF 
investigators need to examine, rather than control for, the contribution of comorbidities to 
outcomes of overweight and obese patients with HF.  
Furthermore, the majority of the previous investigations of the obesity paradox 
have examined all cause death or cardiac related death.5-9, 12 Those that have examined 
all cause hospitalization have controlled for DM in their survival analyses.4, 10, 11 
However, overweight, obesity3, 25 and DM26, 27 can contribute to both cardiovascular3, 26, 28 
and noncardiovascular3, 29 morbidity3 and mortality.25, 26 Thus, examining the combined 
endpoint of all cause hospitalization and death is necessary to completely characterize 
survival in overweight and obese HF patients with and without DM.  
The purpose of this prospective study was to compare event-free survival 
(combined endpoint of all cause hospitalization and death) of overweight and obese HF 
patients with and without DM to normal weight HF patients without DM. Patients were 
divided into five groups according to BMI and the presence or absence of DM: normal 
weight without DM, overweight without DM, overweight with DM, obese without DM and 
obese with DM. Patients were followed for a mean of 389 days to determine differences 
in event-free survival among groups.  
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3. Methods 
3.1 Sample 
 A total of 338 patients with HF were recruited from cardiology clinics at five 
academic medical centers in Kentucky, Indiana, Georgia, Ohio, and Australia. To 
participate, patients had to meet the following eligibility criteria: a) documented diagnosis 
of chronic HF with either preserved or non-preserved systolic function, b) stable on 
medications for three months, c) able to read and speak English, and d) no obvious 
cognitive impairment. Patients were excluded from the study due to a) HF etiology of 
rheumatic heart disease or pregnancy, b) comorbid terminal illness, c) stroke or 
myocardial infarction within the prior three months, or d) body mass index classified as 
underweight (BMI < 18.5 kg/m2). Only seventeen normal weight patients recruited into 
the study had DM, comprising four percent of the sample. Thus this group was not 
included in data analysis due to insufficient sample size.  
3.2 Measurement of variables 
3.2.1 Body mass index and diabetes 
  Weight and height were measured in light clothing without shoes using 
professional grade scales and stadiometers. BMI was calculated as weight in kilograms 
divided by height in meters squared. BMI categories were determined using the National 
Heart Lung and Blood Institute guidelines (normal weight 18.5-24.9 kg/m2, overweight 
25-29.9 kg/m2, obese ≥ 30 kg/m2).30 The presence of DM was determined by self-report 
and medical chart review.  
3.2.2 Event-free survival 
The primary outcome of the study was event-free survival, defined as the 
combined endpoint of all cause hospitalization and death. Research assistants 
interviewed patients monthly by phone to ascertain hospitalizations. To increase 
accuracy of data, patients were asked to keep a diary with dates of all hospital 
admissions, and these data were verified by yearly medical record review performed by 
a research nurse. Dates and causes of death were determined by a combination of 
medical record review, family interview, and county death records. Patients were 
followed for a maximum of four years, with a mean follow-up time of 389 days.  
3.2.3 Depressive symptoms  
The presence of depressive symptoms may contribute to readmission for HF and 
increased mortality in patients with HF.31, 32 Thus we chose to measure depressive 
symptoms and control for them in survival analysis. To assess depressive symptoms 
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research nurses administered the Beck Depression Inventory-II (BDI), a validated and 
reliable tool33 that has been used to predict mortality in patients with HF.32  The BDI is a 
21 item self-report instrument that is designed to measure the severity of depressive 
symptoms. Patients rate their symptoms on a scale of 0 (absence of symptom) to 3 
(persistent or severe symptom). Questions are summed to derive a total score (0-63) 
with higher scores indicating higher depressive symptoms.34 
3.2.4 Other variables of interest  
Research nurses determined age, gender, and New York Heart Association 
(NYHA) functional class through patient interview. Medications were also determined by 
patient interview and verified using the medical record. Most recent ejection fraction was 
obtained by medical record review.  
3.3 Procedure 
 Approval of the study was obtained from the Institutional Review Board at each 
study site. Patients were screened for eligibility by research nurses and approached 
during clinic visits. Research nurses then obtained informed written consent and 
scheduled each patient an appointment at the General Clinical Research Center 
(GCRC) at the recruitment site. At the GCRC height and weight were measured by 
GCRC research staff, and research nurses interviewed patients regarding age, gender, 
NYHA class, medication use, depressive symptoms and DM. The medical record was 
reviewed to obtain the most recent ejection fraction and to verify medications and the 
presence of DM. Patients were followed by research assistants and a research nurse for 
hospitalizations and death as previously described.  
3.4 Data analysis 
Patients were categorized into five groups based on BMI category and the 
presence or absence of DM. Group comparisons of gender, NYHA class, and prescribed 
diuretics, beta blocker and angiotensin converting enzyme (ACE) inhibitors were 
determined using chi square statistic and standardized residuals. Comparisons of age, 
left ventricular ejection fraction (LVEF) and BDI score were determined using one-way 
analysis of variance (ANOVA) with Tukey’s post hoc test.  
Cox regression analysis was conducted to determine differences in event-free 
survival among the groups using normal weight patients without DM as the reference 
group. Variables entered into the model based on clinical relevance were age, gender, 
LVEF, NYHA class (I/II, III, IV), BDI score and ACE inhibitor use. All analyses were done 
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using Predictive Analytics Software version 16.0 and p values < .05 were considered 
statistically significant.  
4. Results 
4.1 Patient characteristics  
Patient characteristics are displayed in Table 2.1. Obese patients without DM 
were younger than normal weight patients, overweight patients and obese patients with 
DM, while obese patients with DM were only younger than normal weight patients. 
Obese patients (with and without DM) had a higher EF than the normal weight patients. 
A greater percentage of patients taking diuretics were overweight with DM, obese 
without DM or obese with DM. There were no other statistically significant differences in 
patient characteristics among groups.  
4.2 Event-free survival 
A total of 138 (41%) patients experienced an event over a mean follow up time of 
389 days. Of these 73 were cardiac related and 65 were non-cardiac related death or 
hospitalization (Table 2.2). The Cox regression model is displayed in Table 2.3. Survival 
curves are displayed in Figure 2.1.  
Age and BDI score were significant predictors of event-free survival. For every 
one point increase in BDI score the risk of all cause hospitalization and death increased 
by four percent. There were also significant differences in survival among the DM and 
BMI groups. Overweight patients without DM, overweight patients with DM and obese 
patients with DM had double the risk for all cause hospitalization and death compared 
with normal weight patients without DM. In contrast, there was no difference in survival 
of obese patients without DM compared with normal weight patients without DM.  
5. Discussion 
This was the first study to examine the impact of overweight and obesity in 
combination with DM on survival outcomes of patients with HF. We demonstrated that in 
the presence of DM overweight and obese patients were at increased risk for all cause 
hospitalization and death. Furthermore, the event-free survival that we observed in the 
obese and overweight groups without DM differed from those observed in prior 
investigations. The investigators in these studies demonstrated that overweight and 
obese patients with HF had better survival than normal weight patients while controlling 
for the presence of DM.4, 6, 8, 10, 11 We demonstrated that obese patients without DM had 
similar, rather than better, survival compared with normal weight patients without DM. 
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Additionally, overweight patients without DM had worse survival compared with the 
normal weight group.  
Perhaps the most important difference between our study and each of these 
previous investigations on the obesity paradox was the chosen follow-up endpoint. 
Horwich et al5 evaluated only cardiac related mortality in systolic HF patients referred for 
heart transplant evaluation and found that overweight and obese patients had better 
survival at 2 years and similar survival at 5 years. Lavie et al,6 Gustafsson et al,8 Davos 
et al9 and Arena et al12 used all cause mortality or cardiac related mortality as the 
outcome in survival analyses of patients with less advanced HF, and all demonstrated 
lower risk in overweight and obese patients. Two of the three remaining investigations 
on the obesity paradox, those conducted by Curtis et al4 and Bozkurt et al,11 examined  
all cause hospitalization as one of the outcomes investigated in the study. These 
investigators found no difference in risk for all cause hospitalization among BMI groups, 
however DM was controlled for in all of these analyses thus obscuring the contribution of 
DM to this outcome.  
In contrast we examined the combined endpoint of all cause hospitalization and 
death. Obesity3 and DM27, 29 contribute to morbidity3, 27, 29 as well as mortality,25, 26, 28 and 
thus examining only death or cardiac related death would have provided an incomplete 
picture of survival. Secondly, overweight, obesity3, 28 and DM26, 27, 29 contribute to both 
cardiovascular26, 28 and noncardiovascular3, 27, 29 morbidity and mortality, and thus 
examining only cardiac related events would have provided an incomplete picture of 
survival as well. In our study, 47% of events were due to reasons other than HF or other 
cardiovascular causes. If we had chosen to only examine cardiac related outcomes we 
would have neglected nearly half of the events that occurred. The use of the combined 
endpoint of all cause hospitalization and death is necessary to fully characterize survival 
in overweight and obese patients with HF and to aid health care professionals in making 
weight recommendations for these patients.  
There has been only one study, by Kenchaiah et al10 that investigated the 
combined endpoint of all cause hospitalization and death as in our study. This was an 
analysis of 7599 patients enrolled in the Candesartan in Heart Failure: Assessment of 
Reduction of Mortality and Morbidity (CHARM) program. Cox regression analysis 
showed no difference in all cause hospitalization and death among BMI groups after 
controlling for the presence of DM. Similarly, we found that obese patients without DM 
had similar risk compared with normal weight patients without DM. However, our results 
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contrast with these in that overweight patients without DM were at higher risk. The 
reasons for these differences in results are unclear. It may be speculated that not all 
events were captured in one or both of these studies. The CHARM trial did not specify 
their methods for determining events and as such we cannot speculate on the 
completeness of their survival data. However, we used multiple approaches to determine 
dates and causes of events: monthly patient interview to capture events that occurred 
outside of the primary hospital site and medical record review to verify the dates and 
causes of these events. For this reason, our data provide a more comprehensive 
assessment of event-free survival. It should be noted that the investigation by Kenchaiah 
et al10 was initiated more than 10 years ago. With the exception of one study examining 
cardiac mortality,12 all of the earlier investigations of the obesity paradox were initiated 
14-19 years ago4, 6, 8, 9, 11 and in one instance nearly 30 years ago.5  The management of 
HF continues to advance35 and data gathered for these analyses may not represent 
outcomes of HF patients treated with current therapies.  
There has been some suggestion that the relationship of BMI to outcomes may 
vary by the presence of preserved and nonpreserved systolic function. Gustafsson et al8 
found that in patients with systolic HF, the overweight and obese groups had worse 
survival compared with normal weight groups, while in those with preserved systolic 
function obese patients had improved outcomes. Our study included both patients with 
preserved and nonpreserved EF. However, multiple other investigations have found 
improved survival with higher BMI in those with systolic HF5, 6, 36 or after stratifying by 
EF.4, 10, 11 Thus it is unlikely that our inclusion of patients with both preserved and 
nonpreserved EF contributed to these differences.  
Our results also confirmed the observation that patients with HF and DM have 
shorter event-free survival than patients without DM. Both overweight patients with DM 
and obese patients with DM were at increased risk for all cause hospitalization and 
death. The Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry18 
produced some of the first data on survival of patients with both HF and DM. In this trial 
of 12,873 patients, DM was an independent predictor of all cause mortality, HF 
hospitalization and all cause hospitalization over one year follow up. Several other large 
retrospectively analyzed clinical trials have found similar results over longer follow up 
times.14, 19 In addition to clinical trials, population studies20, 21 have also shown that 
patients with both HF and DM have higher risk of all cause death. Although BMI was 
controlled for in the survival analyses of some of these clinical trials and population 
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studies,17, 19-21, 23, 24 this is the first study to investigate the impact of DM on outcomes of 
overweight and obese HF patients in comparison with normal weight non-DM HF 
patients.  
5.1 Limitations  
Several limitations in our study are noted. First, the mean follow-up time for our 
study was 389 days or 13 months. Although we followed patients for a maximum of 4 
years, our results may be more representative of short-term rather than long-term 
outcomes. Second, we did not use diagnostic measures such as oral glucose tolerance 
testing to determine the presence of DM. Rather, this information was gathered through 
self-report and verified using the medical record if patients were uncertain if they had this 
diagnosis. It is possible that some patients may have been unaware that they had DM or 
were not yet diagnosed and may have been incorrectly grouped as overweight non-DM 
or obese non-DM. As a result the overweight non-DM group may have included 
uncontrolled DM causing this group to have greater risk compared to the normal weight 
non-DM group. Similarly, the inclusion of uncontrolled DM patients in the obese non-DM 
group may have caused this group to appear to have similar, rather than better survival 
compared to the normal weight group without DM. We also did not collect data on blood 
glucose control such as hemoglobin A1c, and consequently we do not know how well 
controlled patients with DM were. Research investigating the impact of blood glucose 
levels on survival of overweight and obese HF patients with DM is needed.  
6. Conclusions  
 In the presence of DM overweight and obese HF patients were at increased risk 
for all cause hospitalization and death compared with normal weight HF patients without 
DM. Overweight patients without DM were also at increased risk. In contrast, obesity in 
the absence of DM did not contribute to worse survival, suggesting that obesity in the 
absence of DM does not convey greater risk of all cause hospitalization and death.  
 There is little guidance and little consensus among current HF management 
guidelines regarding weight loss recommendations for overweight and obese patients. 
The American College of Cardiology/American Heart Association guidelines are 
completely silent regarding weight loss recommendations for both overweight and obese 
patients.35  The European Society of Cardiology HF management guidelines recommend 
weight loss for obese patients only,37 while the Heart Failure Society of America 
recommends weight loss only for patients with obesity related syndromes such as 
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obesity-cardiomyopathy or obesity-hypoventilation syndromes.38 No recommendations 
are made for overweight patients in any of these guidelines.  
This lack of consensus reflects the current level of evidence regarding survival of 
overweight and obese patients with HF. Our understanding of this relationship has been 
limited by two gaps in the available evidence: 1) the contribution of obesity associated 
comorbidities, such as DM, to survival of overweight and obese patients was not 
investigated and 2) previous investigators did not consider the impact of overweight and 
obesity on all cause hospitalization and death. Rather, previous investigators considered 
only death, cardiac related death or hospitalizations after controlling for DM. Our 
investigation addressed both of these gaps and clarified the paradoxical relationship 
between overweight and obesity and survival by examining the contribution of DM to all 
cause hospitalization and death. This new evidence will assist with development of more 
comprehensive body weight recommendations for patients with HF.  
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Table 2.1 Patient characteristics by body mass index and diabetes group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
characteristics 
Normal 
weight 
non-DM 
 
n = 54 
Overweight 
non-DM 
 
 
n = 60 
Overweight 
DM 
 
 
n = 36 
Obese 
non-DM 
 
 
n = 92 
Obese DM 
 
 
 
n = 96 
P Value 
Gender,  
Women 
 
 
19 (35) 
 
15 (25) 
 
10 (28) 
 
36 (39) 
 
31 (32) 
 
     .421 
Age,  years 
 
66 ±12 62 ±11 67 ±11 56 ±12 61 ±9      ≤ .001 a,b,c,d,f 
LVEF, % 
 
30 ±14 33 ±13 30 ±13 37 ±15 38±15      ≤.002 a,b,e 
NYHA Class  
--I/II 
--III 
--IV  
 
31 (57) 
17 (32) 
6 (11) 
 
 
34 (57) 
21 (35) 
5 (8) 
 
12 (33) 
18 (50) 
6 (17) 
 
47 (51) 
39 (42) 
6 (7) 
 
39 (41) 
40 (42) 
17 (18) 
 
     .093 
BDI 
 
9.6 ± 7.8 10.7 ± 8.7 10.3 ± 9.8 10.1 (8) 12.2 (9.8)      .384 
Diuretics  
 
31 (59) 42 (70) 31 (86) 75 (82) 75 (76)      .008 
Beta blocker 
 
51 (94) 52 (87) 30 (83) 86 (94) 80 (83)      .101 
ACE inhibitor  36 (67) 44 (73) 26 (72) 68 (74) 71 (74)      .888 
Values are n (%) or mean ± standard deviation. a, normal weight versus obese non-DM; b, normal weight 
versus obese DM; c, overweight non-DM versus obese non-DM; d, overweight DM versus obese non-DM; 
e, overweight DM versus obese DM; f, obese non-DM versus obese DM. 
DM, diabetic; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional class; 
BDI, Beck Depression Inventory; ACE, angiotensin converting enzyme.  
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Table 2.2 Number of cardiac and non-cardiac hospitalizations and deaths per group  
 
 
 
 
 
 
 
 
 
 
Event Normal 
weight  
non-DM 
Overweight 
non-DM 
Overweight 
DM 
Obese  
non-DM 
Obese 
DM 
 
Total 
Sample 
Cardiac  8(53) 19(68) 10(56) 20(65) 16(35) 73(53) 
Non-cardiac 7(47) 9(32) 8(44) 11(35) 30(65) 65(47) 
Total 15 28 18 31 46 138 
Values are n(%); DM, diabetic; cardiac, hospitalizations and deaths due to HF or other 
cardiovascular causes; non-cardiac, hospitalizations and deaths due to non-cardiovascular causes 
18 
Table 2.3 Hazard ratios for all cause hospitalization and death 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Exp(B) 95% 
Confidence 
Interval 
P Value 
Age 
 
1.01 1.0 1.03 .045 
Gender 
 
.93 .63 1.37 .701 
NYHA IV 
 
1.20 .72 2.00 .477 
LVEF 
 
.99 .98 1.00 .075 
ACE inhibitor 
 
.81 .55 1.19 .279 
BDI 
 
1.04 1.02 1.06 <.001 
Overweight non-DM 
 
2.13 1.12 4.05 .021 
Overweight DM 
 
2.05 1.02 4.12 .044 
Obese non-DM 
 
1.53 .80 2.93 .196 
Obese DM 2.09 1.14 3.83 .017 
NYHA, New York Heart Association functional class; LVEF, left 
ventricular ejection fraction; ACE, angiotensin converting 
enzyme; BDI, Beck Depression Inventory; DM, diabetic  
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Figure 2.1 Cox regression survival curve for body mass index and diabetes groups   
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal weight without diabetes 
Overweight without diabetes 
Overweight with diabetes 
Obese without diabetes 
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CHAPTER THREE: 
Higher Levels of Soluble TNF-alpha Receptors in Overweight and Obese Heart 
Failure Patients with Diabetes 
1. Synopsis 
 Higher levels of inflammation may contribute to poorer event-free survival in 
overweight and obese HF patients with DM. TNFα and its soluble receptors may 
contribute to the development and progression of heart failure (HF). Similarly, TNFα 
contributes to the complications associated with diabetes (DM) and higher levels of 
inflammatory markers have been demonstrated in patients with DM compared with non-
DM controls. Whether HF patients with DM have higher levels of inflammatory markers 
compared to HF patients without DM has not been investigated.  
 The purpose of this investigation was to compare levels of inflammatory markers 
(sTNF-R1 and sTNF-R2) among normal weight, overweight, and obese patients with HF 
with and without DM as a comorbidity.  
 A total of 343 patients were recruited from HF clinics. Fasting blood draws were 
taken and levels of sTNF-R1 and sTNF-R2 were measured by ELISA. Weight and height 
were measured using professional grade scales and stadiometers, and from these 
values body mass index (BMI) was calculated. The presence of DM was determined by 
patient interview and verified using the medical record. Patients were stratified into five 
groups: normal weight (18.5-24.9 kg/m2) without DM (n=52), overweight (25-29.9 kg/m2) 
without DM (n=63), overweight with DM (n=36), obese (≥ 30 kg/m2) without DM (n=100) 
and obese with DM (n=92). Analysis of variance with Tukey’s post hoc test was used to 
determine differences in inflammatory markers among groups.  
 Obese patients with DM had higher levels of sTNF-R1 compared with all non-DM 
groups (normal weight p< .05; overweight p≤.001; obese p ≤.001). Overweight patients 
with DM had higher levels of sTNF-R1 compared with overweight (p = .008) and obese 
(p=.008) patients without DM. Levels of sTNF-R2 were higher in obese patients with DM 
compared with obese (p ≤.001) and overweight patients (p ≤.001) without DM. 
Overweight patients with DM did not have higher levels of sTNF-R2 compared with any 
group.  
 The results of this investigation demonstrate that diabetes is associated with 
higher levels of inflammatory markers in overweight and obese patients with HF. Higher 
levels of inflammation may contribute to worse event-free survival in obese HF patients 
with DM.  
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2. Introduction 
Increased levels of proinflammatory cytokines have been reported in patients 
with heart failure (HF)1-7  with higher levels associated with worsening New York Heart 
Association functional class.2, 4-6  The proinflammatory cytokine tumor necrosis factor-
alpha (TNFα)2, 4-9  and its two soluble receptors, TNF receptor 1 (sTNF-R1) and TNF 
receptor 2 (sTNF-R2),4-6, 8 are among  the inflammatory markers  commonly elevated in 
patients with HF. TNFα may promote the progression and clinical manifestations of HF10, 
11 through its negative inotropic effects and through its contribution to cardiac 
remodeling.11, 12  Both TNFα13 and its receptors14, 15 have been shown to predict mortality 
in patients with HF.  
Similarly, systemic inflammation is present in patients with diabetes (DM), a 
common comorbidity in patients with HF.16-19  Several investigators have demonstrated 
that higher levels of TNFα20-23  are present in patients with DM versus non-diabetic 
individuals. Although the role of TNFα is still being clarified,24 it may contribute to insulin 
resistance25 and the complications associated with DM.24, 26-31 
The purpose of this study was to compare levels of inflammatory markers (sTNF-
R1 and sTNF-R2) among normal weight, overweight, and obese patients with HF with 
and without DM as a comorbidity. Results from our previous work suggest that obese 
and overweight HF patients with DM were at increased risk for all cause hospitalization 
and death compared with normal weight HF patients without DM.32 Consequently, we 
hypothesized that overweight and obese patients with HF and DM would have higher 
levels of inflammatory markers compared with normal weight, overweight and obese HF 
patients without DM. Higher levels of inflammatory markers may explain, in part, the 
shorter event-free survival we observed in patients with HF and DM. Patients were 
grouped according to the presence or absence of DM and by body mass index (BMI) 
categories.  
3. Methods 
3.1 Sample 
A total of 343 patients were recruited from cardiology clinics at three academic 
medical centers:  the University of Kentucky, Indiana University and Emory University. 
To be eligible for the study patients had to a) have documented chronic heart failure with 
either preserved or nonpreserved systolic function b) be stable on medications for three 
months c) be able to read and speak English and d) have no obvious cognitive 
impairment. Patients were excluded from the study if they had a) heart failure of 
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rheumatic or valvular etiology, b) a terminal illness, c) an autoimmune disease, d) a 
myocardial infarction within the last three months, or e) end-stage renal disease 
3.2 Measurement of variables 
3.2.1 Inflammatory markers 
 The two soluble receptors for TNFα, sTNF-R1 and sTNF-R2, were measured in 
all patients. After TNFα binding sTNF-R1 and sTNF-R2 may be internalized, but are also 
shed from the surface of cells and released into circulation.10 Consequently,  sTNF-R1 
and sTNF-R2 are considered markers of TNFα activity.10  Plasma levels of the soluble 
receptors and TNFα were measured using commercially available enzyme-linked 
immunosorbent assay (ELISA) kits (Alpco Immunoassays) in the core laboratory of the 
University of Kentucky General Clinical Research Center (GCRC). All samples were run 
in duplicate with the average of the samples used. Sample assays were repeated if the 
coefficient of variation was greater than 10%.  
3.2.2 Body mass index and diabetes  
Weight and height were measured in light clothing and without shoes using 
professional grade scales and stadiometers. BMI was calculated as weight in kilograms 
divided by height in meters squared. BMI categories were determined using the National 
Heart Lung and Blood Institute guidelines (normal weight 18.5-24.9 kg/m2, overweight 
25-29.9 kg/m2, obese ≥ 30 kg/m2).33  The presence of diabetes was determined by self-
report and verified by chart review.  
3.2.3 Other variables of interest 
  Age, gender and New York Heart Association (NYHA) functional class were 
determined through patient interview. Medication use was determined through patient 
interview and verified using the medical record. Most recent ejection fraction and HF 
etiology were obtained by medical record review. Comorbidities were determined using 
the Charlson Comorbidity Index.34  At enrollment patients were interviewed regarding the 
presence of comorbidities. Each comorbidity is assigned a point value based on the 
seriousness of each condition. Points are summed to derive a total score, which can 
range from 0-34. Total scores were used to compare differences among groups 
excluding DM. This instrument has been demonstrated to be a valid and reliable 
instrument.34, 35  It has been shown to predict mortality, hospital length of stay, number of 
hospitalizations and hospital charges.34, 35   
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3.3 Procedure 
Approval for the study was obtained from the Institutional Review Board at each 
study site. Patients meeting inclusion criteria were identified by clinic staff and 
approached during clinic visits. The study was explained, and written, informed consent 
was obtained for those agreeing to participate. Research nurses then scheduled patient 
appointments at the GCRC at their respective institutions. All appointments were made 
in the morning. Fasting blood draws were taken and height and weight were measured 
by GCRC research staff at these appointments. Research nurses interviewed patients to 
determine age, gender, NYHA class, medication use and comorbidity score. The 
medical record was reviewed by research nurses to verify medication use, the presence 
of DM, HF etiology and the most recent ejection fraction. Plasma collected at Emory 
University and Indiana University was frozen and shipped on dry ice to the GCRC core 
laboratory at the University of Kentucky and stored at -80° Celsius until analyzed for 
sTNF-R1 and sTNF-R2.  
3.4 Data analysis 
Patients were divided into five groups based on BMI and the presence or 
absence of DM: normal weight without DM, overweight without DM, overweight with DM, 
obese without DM and obese with DM. Only 15 normal weight patients had DM, making 
up only four percent of the total sample. Thus normal weight patients with DM were not 
included in the analysis due to insufficient sample size.  
Differences in mean plasma levels of soluble receptors were determined using 
one-way analysis of variance (ANOVA) with Tukey’s post hoc test. Because values were 
not normally distributed they were mathematically transformed for the purposes of 
analysis. Non-transformed values are reported. Differences in group characteristics were 
determined using chi square statistic for categorical variables or ANOVA for continuous 
variables. Predictive Analytics Software version 16.0 was used for all analyses with p 
values < .05 considered statistically significant.  
4. Results 
4.1 Patient characteristics 
Characteristics for each group are displayed in Table 3.1. Obese patients were 
younger, had a higher EF and a greater percentage were of a minority than normal 
weight and overweight groups. There was a lower percentage of women in the 
overweight groups. Ischemic etiology was more common in the overweight DM group 
and least common in obese non-DM and obese DM groups. Patients with DM were more 
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frequently on a cholesterol lowering agent and had a higher mean comorbidity score. A 
greater percentage of overweight patients with DM and obese patients with and without 
DM were in NYHA classes III and IV.  
4.2 sTNF-R1 and sTNF-R2 
Differences in inflammatory marker values are displayed in Figures 3.1 and 3.2. 
The obese group with DM had higher sTNF-R1 levels than all three groups without DM, 
while the overweight group with DM had higher sTNF-R1 levels than the overweight and 
obese groups without DM (Figure 3.1). sTNF-R2 levels were higher in obese patients 
with DM compared with overweight and obese patients without DM. There were no 
significant differences in the overweight DM group compared with the three non-DM 
groups (Figure 3.2). Overweight and obese patients without DM had similar levels of 
both sTNF-R1 and sTNF-R2 compared with normal weight patients.                                                                                                                                                                                                                                                                                                                                                                                                                         
5. Discussion 
This was the first study to compare levels of inflammatory markers in overweight 
and obese HF patients with DM to normal weight, overweight and obese HF patients 
without DM. sTNF-R1 levels were higher in obese HF patients with DM compared to all 
non-DM groups. Overweight DM patients also had higher levels of sTNF-R1 compared 
with overweight and obese non-DM patients. Similarly, higher levels of sTNF-R2 were 
present in obese patients with DM compared with overweight and obese patients without 
DM. These results partially confirm our hypothesis that patients with DM have higher 
levels of inflammatory markers than patients without DM. Higher levels of inflammation 
may be contributing to worse all cause hospitalization and death in obese HF patients 
with DM.  
Higher levels of inflammatory markers, including TNFα, have been demonstrated 
in patients with HF.2-5 Levine et al1 published one of the first studies demonstrating 
higher TNFα levels in these patients. In 33 patients with chronic HF, mean TNFα values 
were 13 times higher than levels in age-matched controls. Several other investigators 
have also reported this relationship, both for TNFα2, 4, 36 and its soluble receptors,4-6, 8 but 
unlike our study, these levels were not compared among HF patients with and without 
DM. Similarly, higher levels of TNFα have also been reported in patients with DM versus 
non-DM controls,20, 21 but these studies were not conducted in patients with HF.  
Higher levels of TNFα in HF patients with DM may contribute to worse all cause 
hospitalization and death either through effects on the myocardium or through 
contribution to the microvascular complications associated with DM. In addition to 
p =.008 p =.008 
p≤ .001 
p <.05 
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contributing to the cardiac remodeling and decreased myocardial contractility observed 
in HF,10, 11 TNFα is also involved in the microvascular complications associated with 
DM,37 such as  diabetic retinopathy,31 nephropathy29  and neuropathy.30, 38 Higher levels 
of TNFα have been demonstrated in DM with these complications in comparison to DM 
without these complications.39-42  
Although prior investigators have demonstrated elevated levels of TNFα in 
patients with HF, it should be noted that in previous studies, TNFα was not consistently 
elevated. Dutka et al9 measured TNFα in 16 NYHA class IV patients at three month 
intervals for one year. In all patients TNFα could not be detected on at least one 
occasion. Munger et al3 were unable to detect any difference in TNFα values between 
NYHA class II-IV HF patients and individuals without HF, while Lommi and colleagues43 
were only able to detect significant differences in hepatic venous measures of TNFα, but 
not in peripheral measures. The results of these studies may be due to the fact that 
TNFα  primarily operates in autocrine and paracrine manners44 or has a short half-life of 
about 30 minutes.45   
For these reasons we measured levels of the soluble receptors for TNFα. In 
contrast to the autocrine and paracrine manners in which TNFα operates,44 the soluble 
receptors  are cleaved from the surface of the cell and released into circulation after 
being bound by TNFα.10 As a result these receptors can be used as markers of TNFα 
activity.10 The roles of sTNF-R1 and sTNF-R2 are still being clarified, but recent studies 
in mice have suggested that sTNF-R1 mediates hypertrophy and the other cardiac 
remodeling effects of TNFα, while sTNF-R2 acts to ameliorate these effects.46, 47  Given 
this it is interesting that sTNF-R1 levels were elevated in obese patients with DM, and 
this same group was also at greater risk of all cause hospitalization and death as 
demonstrated in our previous study.32  Thus these higher levels of inflammation may 
partially explain why obese patients with DM had worse survival compared with normal 
weight non-DM patients.  
Whether higher levels of inflammation in overweight DM patients contributed to 
worse all cause hospitalization and death in our previous study remains unclear from this 
investigation. Although the overweight DM group did demonstrate higher levels of sTNF-
R1 compared with overweight non-DM and obese non-DM patients, this group did not 
have higher levels in comparison with normal weight patients. This lack of a statistically 
significant difference may be due to the relatively small sample size for overweight DM 
patients. This was the smallest group with only 36 patients in comparison with 52, 63, 
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100 and 92 patients in the normal weight, overweight non-DM, obese non-DM and 
obese-DM groups respectively.  
We did not demonstrate the same differences in sTNF-R2 levels. Rather, levels 
of sTNF-R2 in obese DM patients were not different compared with the normal weight 
non-DM group and overweight patients with DM did not have higher levels compared 
with any group. The reasons for this are unclear. Because the soluble receptors are 
cleaved and released after TNFα binding,10 one would expect that higher levels of TNFα 
would be reflected by higher levels of both soluble receptors. Given the autocrine and 
paracrine manners in which TNFα operates44 it is tempting to speculate that TNFα 
production in patients with DM is higher only in those cells with a higher expression of 
sTNF-R1 but is produced at similar levels in those cells that preferentially express sTNF-
R2. sTNF-R1 is constitutively expressed in virtually all cell types with the exception of  
erythrocytes while sTNF-R2 is preferentially expressed in endothelial and hematopoietic 
cells.48  However, TNFα is involved in vascular dysfunction associated with DM,27, 49 and 
thus it would be expected that endothelial expression of TNFα would be up-regulated in 
patients with DM, translating to increased levels of sTNF-R2. The greater likelihood is 
that our sample size was insufficient to demonstrate significant differences in sTNF-R2 
levels. Larger sample sizes may be needed to demonstrate differences in sTNF-R2 
levels among these groups.  
It should also be noted that a greater percentage of the overweight and obese 
patients with DM were taking cholesterol lowering agents. Statins are a subclass of 
cholesterol lowering agents that have been demonstrated to lower plasma markers of 
inflammation.50 Although we did not have data regarding the use of statins in this 
investigation, it is possible that a greater degree of use of these agents by patients with 
HF and DM could have caused these patients to have lower levels of sTNF-R1 and 
sTNF-R2 than would have been demonstrated otherwise. Future research controlling for 
the use of statins will provide a better understanding of the co-morbid effects of DM on 
levels of inflammation in patients with HF.  
Finally, overweight patients without DM were also at greater risk for all cause 
hospitalization and death compared with normal weight non-DM patients, but this group 
did not have higher levels of any inflammatory marker. This indicates that inflammation 
may not be the only contributing factor to worse survival in overweight HF patients 
without DM. More studies are needed to determine other underlying causes of worse all 
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cause hospitalization and death in this group such as acute illness or infections that 
were not induced by higher levels of inflammation. 
5.1 Limitations 
 We assessed DM through patient interview and verified this using the medical 
record rather than through more diagnostic measures such as oral glucose tolerance 
testing. It is possible that some patients may have been unaware that they had DM. As a 
result patients with DM could have been misclassified as non-DM in our study, leading to 
higher levels of inflammatory markers in the non-DM groups. Second, we did not 
measure hemoglobin A1c and therefore cannot make any conclusions about the 
influence of blood glucose control on inflammation in these patients. More research 
investigating this and the effect of blood glucose-lowering lifestyle interventions on 
inflammation in patients with HF are needed. Finally, we had a rather small sample size 
for some groups. Because of these small sample sizes we may not have been able to 
detect all differences in levels of soluble receptors between groups.  
6. Conclusions 
In conclusion, DM as a comorbidity is associated with higher levels of 
inflammation in patients with HF and may be an underlying contributor to increased 
hospitalization and death observed in obese HF patients with DM. However, we also 
found that overweight patients without DM were at increased risk for hospitalization and 
death, but higher levels of inflammation were not present in this group. This indicates 
that while inflammation may be contributing to worse event free survival among obese 
HF patients with DM, it may not be the sole underlying factor in the worse survival 
demonstrated in overweight patients without DM. Further research is needed to 
determine other causes for worse survival in overweight patients without DM. Future 
studies using larger sample sizes are needed to confirm the differences in inflammatory 
marker levels that we observed. Additionally, research investigating if these levels of 
inflammation are related to blood glucose control is needed.  
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Table 3.1 Patient characteristics by body mass index and diabetes group   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
characteristics 
Normal weight 
non-DM 
n = 52 
Overweight 
non-DM 
n= 63 
Overweight 
DM 
n = 36 
Obese 
non-DM 
n=100 
Obese DM 
 
n=92 
P value 
Age, years 
 
64 ± 11 63 ± 13 63 ± 13 56 ± 13 59 ± 10 ≤.01abcd 
Female 
 
22 (42) 12(19) 6(17) 44(44) 31(34) .002 
NYHA class 
  I/II 
  III/IV 
N=341 
 
37 (73) 
14 (28) 
 
 
44(70) 
19(30) 
 
 
17(47) 
19(53) 
 
 
52(53) 
47(48) 
 
 
40(44) 
52(57) 
 
.001 
Ischemic etiology 
N=319 
21(46) 27(46) 22(65) 32(35) 36(41) .049 
LVEF, % 
N=320 
31 ± 14 35±15 31 ± 14 38 ± 15 37 ± 15 <.05a 
ACE inhibitor 
N=334 
29 (59) 43(69) 30 (83) 66(67) 66(75) NS 
ARB 
N=333 
6 (12) 11(18) 4(11) 17(18) 21(24) NS 
Beta blocker 
N=339 
48 (94) 53(84) 31(86) 90(90) 78(88) NS 
CLA 
N=340 
34(65) 42(68) 32(89) 49(50) 75(82) <.001 
Minority 
 
6(12) 9(14) 3(8) 37(37) 32(35) <.001 
Charlson comorbidity 2.1 ± 1.4 2.1 ± 1.5 2.4 ±1.3 1.9 ± 1.2 2.8 ± 1.6 <.001 e 
Values are n(%) or mean ± standard deviation. a. normal weight vs. obese non-DM b. overweight non-DM 
vs. obese non-DM c. overweight DM vs obese non-DM d. overweight DM vs. obese DM e. obese DM vs. 
normal weight, overweight non-DM and obese non-DM 
DM, Diabetic; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ACE, angiotensin 
converting enzyme; ARB, angiotensin II receptor blocker; CLA, cholesterol lowering agent 
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Figure 3.1 Mean sTNF-R1 values for body mass index and diabetes groups  
 
Significant differences between groups were determined using 
Tukey’s post hoc test using log transformed variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p <.001 p =.008 p =.008 
p≤ .001 
p <.05 
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Figure 3.2 Mean sTNF-R2 values for body mass index and diabetes groups  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p ≤.001 
p ≤.001 
Significant differences between groups determined using Tukey’s post 
hoc test using square root transformed variables.   
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CHAPTER FOUR: 
Higher Vegetable Consumption is Associated with Lower Levels of Soluble TNF-
alpha Receptor 1 in Patients with Heart Failure 
1. Synopsis 
 TNFα and its soluble receptors may contribute to the progression of heart failure 
(HF). Higher consumption of fruits and vegetables has been associated with lower levels 
of TNFα and other markers of inflammation in the general population. However, this 
relationship has not been investigated in patients with HF.  
 The purpose of this investigation was to determine if higher fruit and vegetable 
consumption is associated with lower levels of inflammatory markers (sTNF-R1 and 
sTNF-R2) in patients with HF and to identify differences in other food groups among HF 
patients with lower and higher levels of inflammatory markers.  
 A total of 221 patients completed weighed four-day food diaries that were 
reviewed by a registered dietitian. Nutrition Data System for Research software was 
used to determine the number of servings of fruits, vegetables and other food groups. 
Fasting blood samples were taken and levels of sTNF-R1 and sTNF-R2 were 
determined by ELISA. Logistic regression was used to determine the association 
between the number of servings of fruits and vegetables and sTNF-R1 and sTNF-R2 
levels above the median. Differences in the number of servings of fruits, vegetables and 
other food groups among those with sTNF-R1 levels above and below the median were 
determined using independent samples t-test.  
 A higher consumption of vegetables but not fruits was associated with a lower 
risk of sTNF-R1 levels above the median after controlling for age, gender, NYHA class, 
diabetes, waist circumference, body mass index and energy intake (odds ratio=.84 95% 
CI=.72-.99). Neither the consumption of fruits nor vegetables was associated with levels 
of sTNF-R2. Patients with sTNF-R1 below the median consumed a greater number of 
servings of vegetables compared with those with sTNF-R1 levels above the median 
(3.44 ± 2.11 vs. 2.91± 1.78, p=.046). There were minimal differences in the consumption 
of other food groups between those with sTNF-R1 levels above and below the median.  
 The results of this study demonstrate that consumption of higher levels of 
vegetables is associated with lower levels of sTNF-R1 in patients with HF.  
2. Introduction 
Fruits and vegetables are rich sources of antioxidant vitamins and other 
biologically active plant compounds such as polyphenols.1, 2 Their consumption has been 
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associated with decreased risk of chronic disease3-6 and lower levels of inflammatory 
markers such as TNFα , interleukin-67 and C-reactive protein.8-10 These associations 
were evident even after controlling for other variables that may influence inflammation.7-
10 The majority of studies investigating this relationship have been conducted in 
populations free of cardiovascular disease(CVD)7-9 or investigators have controlled for 
the presence of CVD in their analyses.10 No investigation has examined this relationship 
in patients with heart failure (HF).  
Levels of the inflammatory cytokine TNFα11-17 and its soluble receptors sTNF-R1 
and sTNF-R212-14, 16 are elevated in patients with HF when compared with normal 
controls. TNFα  may contribute to the progression of HF18, 19 by decreasing the force of 
heart contraction and by contributing to cardiac remodeling.19, 20 Furthermore, higher 
levels of TNFα,21 sTNF-R1 and sTNF-R222, 23 are associated with poorer survival in 
patients with HF. Thus, identifying nutritional factors that are associated with lower levels 
of these inflammatory markers is of key importance, as it may provide a potential method 
for decreasing inflammation and improving survival. Therefore, the primary purpose of 
this study was to determine if higher fruit and vegetable consumption was associated 
with lower levels of inflammatory markers in patients with HF. In addition, because 
overall healthful dietary patterns have also been associated with lower levels of 
inflammation24-26 it is also of interest to identify differences in other dietary patterns 
among those with lower and elevated inflammatory markers.  
3. Methods 
3.1 Sample 
Two hundred twenty-one patients with HF were recruited from cardiology clinics 
at the University of Kentucky, Indiana University, and Emory University. To be included 
in the study patients had to meet the following eligibility criteria: a) documented 
diagnosis of HF with either preserved or non-preserved ejection fraction, b) on stable 
doses of their medications for three months, and c) able to read and speak English. 
Patients were excluded from the study due to a) HF etiology of rheumatic heart disease 
or pregnancy, b) obvious cognitive impairment, c) terminal illness, d) stroke or 
myocardial infarction in the prior three months, e) autoimmune disease, or f) end-stage 
renal failure.  
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3.2 Measurement of variables 
3.2.1 Inflammatory markers  
To assess proinflammatory activity of TNFα  plasma levels of sTNF-R1 and 
sTNF-R2 were measured. The soluble TNFα  receptors are cleaved from the cell 
membrane and released into circulation after TNFα binding. As such sTNF-R1 and 
sTNF-R2 are used as markers of TNFα  activity.18  Plasma levels were measured using 
commercially available enzyme-linked immunosorbent assay (ELISA) kits (Alpco 
Immunoassays) in the University of Kentucky General Clinical Research Center (GCRC) 
core laboratory. All samples were run in duplicate and the mean of the two 
measurements was used. The analysis was repeated if the coefficient of variation 
between the two measures was greater than ten percent.  
3.2.2 Nutritional intake 
Fruit and vegetable consumption, total energy (kcal) intake, kcal distribution and 
consumption of grains, dairy, meat, fish, and nuts were determined by four-day food 
diary analysis. Patients were supplied with food diaries for recording intake and digital 
electronic food scales. Patients were asked to weigh and record all foods and beverages 
that were consumed during the four day period. In addition, participants were asked to 
record details of food preparation methods, product brand names and recipes when 
possible. The diaries consisted of three weekdays and one weekend day because food 
consumption is typically altered on the weekends in comparison with food consumption 
throughout the week.27 Additional details regarding food diaries are provided in the 
Procedure section (section 3.3) below.  
Food diaries were analyzed using Nutrition Data System for Research (NDSR) 
software (NCC University of Minnesota). This software package includes nutrient data 
on 19,000 foods, 8,000 brand names, and 160,000 food variations that account for 
differences in food preparation methods. Servings of fruits and vegetables and other 
foods were determined using the NDSR Food Group Serving Count System. This 
system counts the number of servings of foods at the whole food level (e.g. whole 
apples, 100% fruit juice, broccoli) and at the ingredient level to capture intake of food 
groups contained in combination foods (e. g. casseroles, soup, lasagna). Serving sizes 
are based on the Dietary Guidelines for Americans 2005.28 The number of servings of 
fruits, vegetables and other food groups was calculated by averaging the number of 
servings of these foods over the four day period. Kcal intake and kcal distribution were 
determined by averaging kcal intake and the percent of kcal from carbohydrate, fat 
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(saturated fat, monounsaturated fat and polyunsaturated fat) and protein over the four 
day period as well.  
 All vegetables with the exception of fried potatoes (e.g. French fries, hash 
browns) were included in the vegetable category and all fruits including 100% fruit juices 
were included in the fruit category. Grains were differentiated as whole or refined grains. 
Whole grains included all grains that were 100% whole grain or in which a whole grain 
was listed as the first ingredient on the label. Dairy foods were differentiated as full 
fat/reduced fat or low fat. Full fat and reduced fat dairy included full fat cheeses, yogurts, 
milk or reduced fat milk. Low fat dairy included fat free and low fat yogurts, 1% and skim 
milk and low fat and fat free cheeses. High fat meats were designated as fried meats 
and fried fish and those meats that were greater than 10% fat by weight. Lean meats 
were considered those that were less than 10% fat by weight and all fish except fried 
fish.  
3.2.3 Other variables of interest 
 We also collected data on other variables that may influence inflammation in 
order to control for these in statistical analysis. Age, gender, and New York Heart 
Association (NYHA) functional class were determined through patient interview. 
Medication use was determined by patient interview and verified using the medical 
record. Weight and height were measured in light clothing without shoes using 
professional grade scales and stadiometers. From these values body mass index (BMI) 
was calculated as weight in kilograms divided by height in meters squared (kg/m2). Waist 
circumference was measured in centimeters at the level of the iliac crest and at the end 
of a normal expiration. Results from our previous investigation demonstrated higher 
levels of inflammation in HF patients with diabetes(DM).29 For this reason we also chose 
to control for DM in statistical analysis. The presence of DM was determined by patient 
interview and verified using the medical record.  
3.3 Procedure 
Approval was obtained from the Institutional Review Board at each of the sites 
involved in the study. After being screened for eligibility patients were approached during 
clinic visits, and informed written consent was obtained. Appointments at the GCRC and 
home visits from a research nurse were then scheduled. The research nurse visited the 
patient one week prior to the GCRC appointment to deliver a food diary and digital food 
scale. At these appointments use of the scale was explained and demonstrated. Patients 
were asked to give a return demonstration weighing items on the food scale and 
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recording in the food diary. Patients were also given pictures to help them estimate 
portion sizes if there were times when they were unable to weigh their food (e.g. dining 
at a restaurant). The research nurse called participants on the day they began their food 
diary to verify understanding and address problems if needed. On the morning following 
the last day of the food diary, patients visited the GCRC to have fasting blood drawn and 
height, weight and waist circumference measured. A registered dietitian reviewed all 
food diaries to verify serving sizes, clarify food preparation methods, and obtain 
additional details. At these appointments research nurses interviewed patients to 
determine age, gender, NYHA class, medication use and presence of DM. The medical 
record was used to verify medication use and the presence of DM. Plasma samples 
obtained at Indiana University and Emory University were shipped on dry ice to the 
University of Kentucky GCRC and stored at -80° C until analyzed.  
3.4 Data analysis 
Logistic regression was used to determine the odds ratios for sTNF-R1 and 
sTNF-R2 above the median. The average number of servings of fruits and the average 
number of servings of vegetables were entered separately into the regression model. 
Additional variables controlled for were age, gender, NYHA class, diabetes, BMI, waist 
circumference and energy intake. Differences in sample characteristics by median 
sTNF-R1 were determined using independent samples t-test for continuous variables 
and chi square for categorical variables. Sample characteristics are displayed by median 
sTNF-R1 because participants were divided by the median of inflammatory markers for 
regressions and because associations between dietary variables and inflammation were 
only apparent for sTNF-R1. Differences in eating patterns were determined by 
independent samples t-test. Predictive Analytics Software version 16.0 was used for all 
analyses with a p < .05 considered statistically significant.  
4. Results 
4.1 Patient characteristics 
Patient characteristics are displayed in Table 4.1. Patients with sTNF-R1 values 
above the median were older and had a higher waist circumference than patients with 
sTNF-R1 values below the median. Also, a greater percentage of patients above the 
median had DM. This corresponds with our previous investigation in which HF patients 
with DM had higher levels of inflammation compared with HF patients without DM.29 
There were no other significant differences in patient characteristics between groups.  
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4.2 Soluble TNFα receptors and fruit and vegetable consumption  
Independent predictors of sTNF-R1 and sTNF-R2 above the median are 
presented in Tables 4.2 and 4.3 respectively. Higher vegetable, but not fruit consumption 
was associated with a lower sTNF-R1 level. There was a 16 % reduction in risk of 
having sTNF-R1 levels above the median for every additional serving of vegetables 
consumed per day. A higher BMI was also associated with a lower risk, while age, being 
female and waist circumference were associated with a higher risk of having sTNF-R1 
levels above the median. In contrast, higher vegetable intake and BMI were not 
associated with lower sTNF-R2 levels. Higher age and waist circumference were the 
only independent predictors of sTNF-R2 levels above the median.  
4.3 Dietary patterns by median sTNF-R1 
Dietary patterns by median sTNF-R1 are displayed in Table 4.4. Those patients 
with sTNF-R1 levels below the median consumed significantly more vegetables 
compared with patients with levels above the median. Similarly, those with sTNF-R1 
levels below the median also consumed more non-lean meats (< 90% lean) compared to 
those above the median. There were no other differences in eating patterns between 
groups.  
5. Discussion 
This is the first study to investigate the association of fruit and vegetable 
consumption with levels of inflammatory markers in patients with HF. Each additional 
serving of vegetables was associated with a 16% reduction in risk of having sTNF-R1 
levels above the median. This association was not found for fruit consumption. Neither 
fruit nor vegetable consumption was predictive of sTNF-R2 levels.  
Prior studies have demonstrated that higher fruit and vegetable consumption is 
associated with lower levels of inflammation in populations without HF. Holt et al7 
investigated this relationship in 285 adolescents. After controlling for age, gender, race, 
energy intake and BMI, investigators found that vegetables but not fruits were inversely 
associated with TNFα levels. Although this study was conducted in a dissimilar 
population, our results are supportive of this relationship. We found that higher 
consumption of vegetables but not fruits was associated with a lower risk of having an 
elevated sTNF-R1 in patients with HF.  
Several other investigations have identified that fruit and vegetable consumption 
is associated with other markers of inflammation, such as C-reactive protein (CRP), in 
non-HF populations. Gao et al10 investigated this relationship in 599 elders. They found 
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that the likelihood of having an elevated CRP was 21% lower per serving of combined 
fruit and vegetable intake. Subsequent investigators have also demonstrated that CRP 
levels decrease with increasing intake of fruit8, 9 and vegetables.9  
In this study the association between vegetable intake and sTNF-R1 was evident 
even after controlling for other factors that may influence levels of inflammatory markers. 
Of particular interest is the inverse relationship between BMI and sTNF-R1 levels. 
Obese and overweight patients with HF have been demonstrated to have better survival 
compared with normal weight patients.30, 31 One postulated explanation of this 
relationship is that overweight and obese patients may have an altered proinflammatory 
cytokine profile.32 Our results support the observation that patients with higher BMI may 
have lower systemic inflammatory activity. However it should be noted that this inverse 
relationship was demonstrated after controlling for waist circumference, which was 
associated with higher risk, indicating the effects of higher BMI independently of 
abdominal obesity.  
Interestingly, DM was not a significant predictor of risk for elevated sTNF-R1 or 
sTNF-R2 levels. This contrasts with our previous study in which higher levels of sTNF-
R1 were found in overweight and obese patients with DM in comparison to overweight 
and obese patients without DM.33 Higher waist circumference is indicative of greater 
abdominal adiposity and is associated with greater risk of type 2 DM than is adipose 
tissue in other regions of the body.34 The results of this study suggest that elevated 
levels of sTNF-R1 in patients with DM may be due to higher waist circumference in 
these patients.  
TNFα has both local effects on the myocardium as well as peripheral effects. It is 
thought to contribute to the progression of HF through its contribution to changes 
associated with cardiac remodeling such as apoptosis, fibrosis, and hypertrophy and 
through depressing myocardial contractility.19, 20 Peripherally TNFα  impairs vasodilation 
of tissues and may thereby contribute to the exercise intolerance characteristic of HF.18  
In addition, it is also thought to induce anorexia and muscle wasting associated with 
cachexia,18 an independent predictor of mortality in patients with HF.35 Although the two 
soluble receptors of TNFα, sTNF-R1 and sTNF-R2, have been associated with poorer 
survival in patients with HF,22, 23 their  functional roles after TNFα  binding are still being 
clarified. While the extracellular domains of sTNF-R1 and sTNF-R2 are very similar in 
structure, their intracellular domains demonstrate significant heterogeneity,36 indicating 
different effects for these receptors. Indeed, recent studies in murine models of HF37 and 
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myocardial infarction38 indicate that sTNF-R1 exacerbates hypertrophy and other TNFα  
induced cardiac remodeling processes, while sTNF-R2 ameliorates these events. These 
investigations underscore the importance of the association we found between higher 
vegetable consumption and lower levels of sTNF-R1. However, we did not find an 
association between vegetable consumption and sTNF-R2 levels. The reasons for this 
are unclear. Because TNF receptors are shed from the surface of the cell after TNFα  
binding, one would expect that lower levels of TNFα  would translate to lower levels of 
both soluble TNF receptors. It is possible that these results are due to a greater 
variability in sTNF-R2 levels over the short-term.39  
Fruits and vegetables may be associated with lower levels of inflammation due to 
their antioxidant compounds. In addition to inflammation, oxidative stress is also thought 
to contribute to the development and progression of HF.40 Oxidative stress leads to the 
binding of the transcription factor NF-kappa B to DNA and the subsequent synthesis of 
proinflammatory cytokines.41 Conversely, proinflammatory cytokines may also induce 
oxidative stress, creating an inflammation-oxidative stress cycle.40 The antioxidants in 
fruits and vegetables may help to decrease oxidative stress by neutralizing free radicals 
and reactive oxygen species42 and thereby reduce systemic inflammation. Several 
nutrients present in fruits and vegetables posses antioxidant properties including vitamin 
A, vitamin C and the carotenoids (i. e. beta carotene, lycopene, lutein, zeaxanthin).42   
Furthermore, other phytochemicals such as polyphenols not only exhibit antioxidant 
properties, but also demonstrate anti-inflammatory effects in in vitro studies.42, 43 Thus 
fruits and vegetables contain a large number of bioactive compounds that may decrease 
inflammation.  
In this investigation the risk of having sTNF-R1 levels above the median was 
16% lower for every additional serving of vegetables consumed. It should be noted that 
the relationship between vegetable consumption and levels of inflammation may not be 
linear. Vegetable consumption may need to reach a certain threshold before decreases 
in sTNF-R1 levels related to vegetable consumption becomes evident. Similarly, there 
may also be an upper level of vegetable consumption above which additional 
consumption provides no benefit. 
It is unclear why fruit consumption was not associated with lower levels of sTNF-
R1 in this study. Both fruits and vegetables are sources of polyphenols1 and antioxidant 
vitamins.44 Although the total antioxidant capacity of several fruits and vegetables has 
been determined,45 we know of no report that has determined that vegetables have a 
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greater antioxidant capacity than fruits. It should be noted that the consumption of fruits 
was relatively low (1.44 and 1.53 servings for groups below and above the median of 
sTNF-R1 respectively) both in this study and in the study by Holt et al7  in which fruit 
consumption was not associated with TNFα levels. It is possible that the association 
between fruit consumption and sTNF-R1 levels does not become evident until intake 
reaches a certain threshold, and thus the effect of fruits on inflammation may not have 
been evident due to a low level of consumption.  
5.1 Limitations 
 The prior investigators of fruit and vegetable consumption and markers of 
inflammation have all used food frequency questionnaires (FFQ) to assess fruit and 
vegetable intake.7-10 While FFQ can provide valuable information regarding usual intake, 
this method relies heavily on the participant’s memory and ability to accurately estimate 
portion sizes.27 In contrast we used weighed four-day food diaries in which participants 
weighed and recorded foods as they were consumed. This method allowed us to capture 
detailed quantitative dietary information that was not subject to recall bias. However, 
although food diaries are considered representative of usual dietary intake27 the cross-
sectional design of this study limits our ability to determine causality. Further research is 
needed to determine if increasing vegetable consumption can lower levels of 
inflammation in patients with HF. Additionally, we did not control for other dietary 
patterns that may be associated with lower levels of inflammation. However, it should be 
noted that with the exception of vegetable consumption, we found minimal differences in 
food patterns in those above and below the median sTNF-R1 level.  
6. Conclusions  
 The present study demonstrates that higher vegetable consumption is associated 
with lower levels of sTNF-R1 in patients with HF independent of other factors that may 
influence inflammation such as age, waist circumference, BMI, NYHA class, and DM. 
Due to the contribution of TNFα to the clinical manifestations and progression of HF, 
research investigating the benefits of lifestyle factors, such as diet, on levels of 
inflammation is warranted. Further research investigating the association of other dietary 
components with inflammation as well as the ability of increased vegetable consumption 
to lower levels of inflammation in patients with HF is needed.  
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Table 4.1 Patient characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
characteristics 
Total 
sample 
 
 
N=221 
sTNF-R1 
below the 
median 
n=111 
sTNF-R1 
above the 
median 
n=110 
P value 
Age 
 
62 ± 12 59 ± 12 64 ± 11 .000 
Gender, women 
 
71 (32) 32 (29) 39 (36) .292 
NYHA 
    I/II 
    III/IV 
 
 
134 (61) 
87 (39) 
 
73 (66) 
38 (34) 
 
61 (56) 
49 (45) 
.117 
BMI 
 
30 ± 8 30 ± 8 30 ± 7 .710 
Waist circumference 
 
102 ± 15 100 ± 16 105 ± 15 .021 
Diabetes 
 
74 (34) 26(23) 48 (44) .001 
ACE inhibitor 
 
148 (69) 76 (70) 72 (68) .776 
Beta Blocker 
 
193 (89) 97 (87) 96 (90) .589 
CLA 83 (75) 85 (77) 168 (76) .664 
Values are n(%) or mean ± standard deviation. NYHA, New York Heart Association 
functional class; BMI, body mass index; ACE, angiotensin converting enzyme; CLA, 
cholesterol lowering agent 
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Table 4.2 Adjusted odds ratios for sTNF-R1 above the median  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Beta Odds ratio 95%  Confidence 
interval 
P value 
Age 
 
0.04 1.04 1.01             1.07 .003 
Gender 
 
1.42 4.14 1.69           10.13 .002 
NYHA III/IV 
 
0.43 1.54 0.83             2.88 .173 
Diabetes 
 
0.64 1.89 0.98             3.64 .058 
BMI 
 
-0.13 0.88 0.80             0.97 .01 
Waist circumference 
 
0.08 1.09 1.04             1.14 .000 
Kcal 
 
0.00 1.00 0.99             1.00 .553 
Fruits 
 
0.08 1.08 0.89             1.33 .439 
Vegetables -0.17 0.84 0.72             0.99 .039 
NYHA, New York Heart Association functional class; BMI, body mass index; Kcal, 
energy in kilocalories 
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Table 4.3 Adjusted odds ratios for sTNF-R2 above the median  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Beta Odds ratio 95%  Confidence 
interval 
P value 
Age 
 
0.04 1.04 1.01              1.06 .009 
Gender 
 
0.54 1.72 0.79             3.72 .171 
NYHA III/IV 
 
0.31 1.36 0.76             2.46 .303 
Diabetes 
 
0.31 1.36 0.72             2.54 .341 
BMI 
 
-0.05 0.96 0.88             1.03 .249 
Waist circumference 
 
0.05 1.05 1.01             1.09 .014 
Kcal 
 
0.00 1.00 0.99             1.00 .584 
Fruits 
 
-0.10 0.90 0.75             1.09 .299 
Vegetables -0.03 0.97 0.84             1.12 .678 
NYHA, New York Heart Association functional class; BMI, body mass index; Kcal, 
energy in kilocalories 
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Table 4.4 Dietary intake by median sTNF-R1 level  
 
 
 
 
 
 sTNF-R1 below the 
median 
sTNF-R1 above the 
median 
P value 
Carbohydrate (% kcal) 
 
47.56 ± 9.23 47.53 ± 8.53 0.975 
Fat (% kcal) 
     Saturated fat  
     MUFA  
     PUFA 
 
35.29 ± 7.49 
11.28 ± 2.8 
13.69 ± 3.47 
7.32 ± 2.2 
35.49 ± 7.58 
11.79 ± 3.01 
13.59 ± 3.55 
7.03 ± 2.32 
0.843 
0.199 
0.844 
0.336 
Protein (% kcal) 
 
17.32 ± 4.13 17.60 ± 4.43 0.632 
Vegetables 
 
3.44 ± 2.11 2.91 ± 1.78 0.046 
Fruits 
 
1.44 ± 1.46 1.53 ± 1.64 0.669 
Grains 
    Refined grains 
    Whole grains 
 
5.06 ± 2.32 
3.87 ± 2.30 
1.38 ± 1.54 
4.55 ± 2.20 
3.57 ± 1.95 
1.08 ± 1.41 
0.091 
0.308 
0.134 
Dairy 
     RF and FF dairy  
     Low fat dairy       
 
1.03 ± 0.99 
0.73 ± 0.82 
0.28 ± 0.63 
1.14 ± 0.96 
0.73 ± 0.64 
0.40 ± 0.85 
0.407 
0.986 
0.229 
Meat and fish 
    HF meat 
    Lean meat and fish 
6.32 ± 3.62 
3.21 ± 2.87 
2.62 ± 1.89 
5.45 ±  3.0 
2.48 ± 2.37 
2.44 ± 2.07 
0.051 
0.04 
0.507 
Nuts and seeds 0.50 ± 1.41 0.52  ±  1.23 0.935 
Values are mean ± standard deviation. Kcal, energy in kilocalories; MUFA, 
monounsaturated fat; PUFA, polyunsaturated fat; RF, reduced fat; FF, full fat; HF, high 
fat 
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CHAPTER FIVE: 
Conclusion 
1. Purpose  
 The purposes of this dissertation were to a) determine the impact of diabetes 
(DM) on event-free survival of overweight and obese patients with heart failure (HF), b) 
explore potential inflammatory related mechanisms underlying differences in survival of 
normal weight, overweight and obese HF patients with and without DM and c) examine 
the association between levels of inflammation and fruit and vegetable consumption in 
patients with HF. To address these purposes three investigations were conducted. This 
chapter is a summary of each investigation, a description of how the results advance the 
current state of the science, and a discussion of implications for future research.  
2. Chapter Two 
Overweight and obesity were associated with increased risk for development of 
heart failure (HF). 1 A  number of studies indicated that overweight and obesity were 
associated with improved survival in patients with established HF.2-9 These seemingly 
conflicting relationships were suggested as a reason for the lack of consensus among 
current HF management guidelines. Two major limitations were identified that may 
contribute to the lack of a guideline consensus. First, the impact of DM on survival of 
overweight and obese patients has not been described. Prior investigators controlled for 
DM in survival analysis,2, 3, 5-7 and thus their results demonstrated the impact of 
overweight and obesity independent of DM. Second, prior investigators only considered 
all cause or cardiac related death3-5, 8, 9 while largely ignoring all cause hospitalization 
and death. The investigators who examined all cause hospitalization and death 
controlled for the presence of DM in the analyses.2, 6, 7 
The investigation presented in Chapter Two addressed these limitations by 
comparing risk of all cause hospitalization and death of normal weight patients without 
DM to overweight and obese HF patients with and without DM. A total of 338 patients 
were recruited from three HF clinics and followed for a mean of 389 days. All cause 
hospitalization and death were determined through patient interview and medical record 
review. In contrast to prior studies in which overweight and obesity were associated with 
better survival,2-9 the results of this investigation demonstrated that in the presence of 
DM, overweight and obese patients with HF had worse event-free survival compared 
with normal weight HF patients without DM. In addition, we demonstrated that when all 
cause hospitalization and death were considered, overweight patients without DM had 
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worse survival compared with normal weight patients. Using this endpoint also 
demonstrated that obese patients without DM had similar survival compared with normal 
weight patients, indicating that obesity did not confer greater risk.  
There are several important implications that can be drawn from this 
investigation. First, the impact of obesity associated comorbidities needs to be 
considered, rather than controlled for in statistical analyses. Controlling for DM 
demonstrates event-free survival of overweight and obese HF patients independent of 
DM and consequently does not identify the impact of this comorbidity on event-free 
survival of overweight and obese patients. Second, the use of all cause hospitalization 
and death in survival analyses provides a better understanding of the effect of obesity on 
health outcomes of patients with HF because overweight, obesity10-12 and DM13, 14 
contribute to both cardiovascular and non-cardiovascular morbidity12, 14 and mortality.10, 
11, 13, 14 Our data provide additional clarity regarding obesity in HF and will assist with 
development of body weight guidelines for overweight and obese patients with HF.  
Third, our data highlight the importance of managing comorbidities, which are an 
under-recognized component of HF care, particularly within the guidelines. 
Recommendations for HF patients with DM primarily focus on the use of 
thiazolidineiones and the safety of medications typically used for the treatment of HF (i.e. 
angiotensin converting enzyme inhibitors, beta blockers, angiotensin receptor blockers) 
with minimal guidance on optimizing care of both comorbidities.15-17 To better inform 
these guidelines and to improve survival of overweight and obese HF patients with DM 
additional research investigating the causes of hospitalization in this patient group is 
needed. Although the causes of HF-related hospitalization in the general HF population 
have been described,18, 19 the causes of non-HF related hospitalization in HF patients 
with DM have not been investigated. Identification of these causes provides an 
understanding of the impact of DM on all aspects of patient health—not just HF-related 
outcomes. Investigating these causes will also guide interventions designed to decrease 
hospital admissions in HF patients with DM and inform guidelines for the care of HF 
patients with DM as a comorbidity.  
3. Chapter Three 
 Higher levels of inflammation were proposed as a contributor to the worse event 
free survival of overweight and obese HF patients with DM demonstrated in Chapter 
Two. Prior studies demonstrated higher levels of TNFα in patients with HF compared 
with normal controls.20-24 Similarly, previous investigators demonstrated higher levels of 
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TNFα in patients with DM compared to individuals without DM.25-28 In Chapter Three it 
was identified that prior studies were limited because investigators that examined levels 
of TNFα in patients with HF did not compare levels among HF patients with and without 
DM. Similarly, those studies in which TNFα levels were measured in people with DM did 
not include patients with HF. Thus, prior to this investigation, it was unknown if HF 
patients with DM have higher levels of inflammatory markers compared with HF patients 
without DM.  
 In the study reported in Chapter Three we addressed this knowledge gap by 
comparing levels of soluble TNFα receptors-1 and -2 (sTNF-R1 and sTNF-R2) in normal 
weight, overweight and obese HF patients with and without DM. A total of 343 patients 
with HF were recruited from HF clinics and stratified by body mass index and the 
presence or absence of DM. Fasting plasma levels of sTNF-R1 and sTNF-R2 were 
measured in all patients. Obese patients with DM had higher levels of sTNF-R1 
compared with all non-DM groups. Overweight patients with DM had higher levels of 
sTNF-R1 compared with overweight and obese HF patients without DM, but there were 
no significant differences compared with normal weight patients. The same differences 
were not apparent for sTNF-R2. Although obese patients with DM had higher levels of 
sTNF-R2 compared with obese and overweight patients without DM, this group did not 
have higher levels compared with normal weight patients. Overweight patients with DM 
did not demonstrate higher levels compared with any group.  
 The results of this study advance the state of the science by demonstrating that 
HF patients with DM have higher levels of inflammatory markers compared with HF 
patients without DM, identifying a potentially modifiable factor for improving survival in 
HF patients with DM. Prior to this investigation, this relationship had not been examined. 
Further, the results of this study identify higher levels of inflammation as a potential 
contributor to worse survival in obese HF patients with DM. However, overweight 
patients with DM did not demonstrate higher levels of any inflammatory marker in 
comparison with normal weight patients. Consequently, whether or not inflammation is 
contributing to worse survival in overweight patients with DM cannot be determined from 
this investigation. The overweight group with DM was the smallest group with only 36 
patients compared with 52, 63, 100 and 92 patients in the normal weight, overweight 
non-DM, obese non-DM and obese DM groups respectively. Thus this study may have 
been underpowered to detect significant differences in levels of sTNF-R1 and sTNF-R2 
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in overweight patients with DM. Further studies with larger sample sizes are needed to 
confirm the differences in soluble receptors demonstrated in this investigation.  
 Measures of blood glucose control, such as hemoglobin A1c were not 
determined in this investigation. Thus, the association between blood glucose control 
and levels of inflammation in overweight and obese HF patients with DM is unknown. 
Future research investigating this and the effect of lifestyle interventions designed to 
improve blood glucose control on levels of inflammation is needed.  
4. Chapter Four 
 In Chapter Four we proposed that higher consumption of fruits and vegetables 
would be associated with lower levels of inflammation in patients with HF, potentially due 
to the antioxidant compounds in fruits and vegetables. In prior studies the consumption 
of higher levels of fruits29-32 and vegetables29, 30, 32 was associated with lower levels of 
inflammation in non-HF populations. This relationship was previously demonstrated for 
TNFα32 and other markers of inflammation including interleukin-632 and C-reactive 
protein.29-31 Prior to our study however, the relationship between fruit and vegetable 
consumption and levels of inflammation had not been investigated in patients with HF.  
 We addressed this gap in the available evidence by testing the association 
between fruit and vegetable consumption and levels of sTNF-R1 and sTNF-R2 in 
patients with HF. A total of 221 patients were recruited from HF clinics. All patients were 
given digital electronic food scales and asked to weigh and record all foods and 
beverages consumed over a four-day period. The consumption of fruits and vegetables 
was determined by taking the average consumption over the four day period. After 
controlling for age, gender, New York Heart Association functional class, DM, body mass 
index, waist circumference, and energy intake, higher vegetable but not fruit 
consumption was associated with lower risk of elevated sTNF-R1 levels. For every 
additional serving of vegetables, the risk of having sTNF-R1 levels above the median 
decreased by 16%. However, neither fruit nor vegetable consumption was associated 
with levels of sTNF-R2. These results suggest that vegetable consumption is associated 
with lower levels of sTNF-R1 in patients with HF even after controlling for other factors 
that may influence inflammation, such as body composition. A low consumption of fruit 
among all patients may explain why fruit consumption was not associated with markers 
of inflammation. Further, a greater variability in sTNF-R2 levels33 may explain the lack of 
association between this inflammatory marker and vegetable consumption.  
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 Our results advance the state of the science by identifying a potentially simple 
way to lower inflammation in patients with HF. TNFα plays a significant role in the 
progression of HF,34 and a modifiable nutrition-related method of lowering inflammation 
could lead to improvements in survival of patients with HF. However, due to the cross-
sectional design of this study, we cannot determine causality. Research testing whether 
increasing vegetable consumption lowers levels of inflammation in patients with HF is 
needed before a definitive recommendation can be made. Additional studies are also 
needed to determine if other food groups and an overall healthy diet are associated with 
levels of inflammatory markers.  
5. Conclusion 
 Prior to these studies there were several gaps in the available evidence 
regarding the impact of DM on event-free survival of overweight and obese patients with 
HF, levels of inflammation in HF patients with DM, and the association between fruit and 
vegetable consumption and levels of inflammatory markers in patients with HF. This 
dissertation advanced the state of the science by a) identifying the impact of DM on all 
cause hospitalization and death in overweight and obese patients with HF and 
consequently clarifying the obesity paradox b) identifying higher levels of inflammatory 
markers as a potential contributor to poorer survival of HF patients with DM and c) 
demonstrating that higher vegetable consumption is associated with lower levels of 
inflammation in patients with HF. Additional research investigating the causes of 
hospitalization in HF patients with DM, the association of blood glucose control and 
healthful dietary patterns with levels of inflammation and the ability of improvements in 
blood glucose control and increased vegetable consumption to lower levels of 
inflammation in patients with HF is needed.  
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